News
T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.
ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback